{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:47:07Z","timestamp":1764510427186,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":951,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Swedish Orphan Biovitrum pharmaceuticals"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.bbmt.2012.03.010","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T13:40:04Z","timestamp":1332596404000},"page":"1455-1461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Melphalan 180 mg\/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL\/min\/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial"],"prefix":"10.1016","volume":"18","author":[{"given":"Muneer H.","family":"Abidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois","family":"Ayash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Al-Kadhimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Ventimiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Lum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Voravit","family":"Ratanatharathorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Uberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2012.03.010_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.thj.6200003","article-title":"Are myeloma patients with renal failure candidates for autologous stem cell transplantation?","volume":"1","author":"San Miguel","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.bbmt.2012.03.010_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1054\/bjoc.2001.1928","article-title":"Glomerular filtration rate prior to high-dose melphalan 200 mg\/m(2) as a surrogate marker of outcome in patients with myeloma","volume":"85","author":"Sirohi","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbmt.2012.03.010_bib4","first-page":"947","article-title":"Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study","volume":"2","author":"Tricot","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2012.03.010_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","article-title":"Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure","volume":"75","author":"Knudsen","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","article-title":"Treatment of multiple myeloma: a comprehensive review","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.bbmt.2012.03.010_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2012.03.010_bib8","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib9","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2012.03.010_bib10","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-08-238196","article-title":"Hematopoietic stem cell transplantation for multiple myeloma beyond 2010","volume":"115","author":"Blad\u00e9","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.03.010_bib11","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-dose intravenous melphalan: a review","volume":"13","author":"Samuels","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.03.010_bib13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/14728214.13.3.511","article-title":"Emerging drugs for chemotherapy-induced mucositis","volume":"13","author":"Keefe","year":"2008","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.bbmt.2012.03.010_bib15","first-page":"477","article-title":"Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant","volume":"16","author":"Schuster","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2012.03.010_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bmt.1704946","article-title":"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation","volume":"35","author":"Spencer","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.03.010_bib17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2004.03.001","article-title":"Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study","volume":"10","author":"Phillips","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.03.010_bib18","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1073\/pnas.86.3.802","article-title":"Purification and characterization of a newly identified growth factor specific for epithelial cells","volume":"86","author":"Rubin","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2012.03.010_bib19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/annonc\/mdl332","article-title":"Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis","volume":"18","author":"Blijlevens","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2003.10.079","article-title":"Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant","volume":"21","author":"Meropol","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib21","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1056\/NEJMoa040125","article-title":"Palifermin for oral mucositis after intensive therapy for hematologic cancers","volume":"351","author":"Spielberger","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"29","key":"10.1016\/j.bbmt.2012.03.010_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/oxfordjournals.jncimonographs.a003433","article-title":"Protection against mucosal injury by growth factors and cytokines","author":"Booth","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.bbmt.2012.03.010_bib23","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/annonc\/mdq059","article-title":"A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma","volume":"21","author":"Kobbe","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.03.010_bib25","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2275::AID-CNCR25>3.0.CO;2-Q","article-title":"The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies","volume":"82","author":"Ruescher","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2012.03.010_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/322595","article-title":"Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients","volume":"33","author":"Lark","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2012.03.010_bib27","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1200\/JCO.2001.19.8.2201","article-title":"Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation","volume":"19","author":"Sonis","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.03.010_bib28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.bmt.1702447","article-title":"Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for hematological malignancy: an overview","volume":"25","author":"Blijlevens","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.03.010_bib29","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.179.3.831","article-title":"Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor","volume":"179","author":"Pierce","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2012.03.010_bib30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.bmt.1705384","article-title":"A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation","volume":"37","author":"Lilleby","year":"2006","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911200122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911200122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:42:21Z","timestamp":1761057741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911200122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S108387911200122X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2012.03.010","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melphalan 180 mg\/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL\/min\/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2012.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}